[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection
Status: | Terminated |
---|---|
Conditions: | Infectious Disease, Orthopedic, Diabetes |
Therapuetic Areas: | Endocrinology, Immunology / Infectious Diseases, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | April 2013 |
End Date: | February 2014 |
Exploration of the Use of [124I]FIAU Positron Emission Tomography-Computed Tomography Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection.
This protocol will evaluate the sensitivity and specificity of [124I]FIAU as a diagnostic
imaging agent for the detection of osteomyelitis in patients with diabetic foot infection.
imaging agent for the detection of osteomyelitis in patients with diabetic foot infection.
Inclusion Criteria:
1. Male and female patients >/= 18 years on the day of signing consent.
2. A diagnosis of diabetes mellitus, type I or II, as evidenced either by HbA1c>6.5% or
receipt of antidiabetic medication at time of enrollment.
3. Ability to provide informed consent
4. An inframalleolar ulcer of perfusion, extent/size, depth/tissue loss, infection and
sensation (PEDIS) grade 2 or 3. At the discretion of the Investigator, patients with
PEDIS grade 4 infections may be included if they are sufficiently stable.
5. For females of childbearing potential, a negative urine pregnancy test on the day of
dosing.
6. For females of childbearing potential, a willingness to use 2 methods of
contraception for 30 days after receiving [124I]FIAU.
7. Ability to return for all study assessments.
8. Clinically euthyroid, or on stable thyroid replacement therapy.
Exclusion Criteria:
1. Patients who ar unable to comply with study requirements.
2. Indication, in the opinion of the principal Investigator for urgent surgery that
would preclude the time needed for PET-CT scanning, or clinical instability that
precludes PET-CT scanning.
3. History of an inherited mitochondrial disorder (eg. Leber's hereditary neuropathy,
neuropathy, ataxia, retinitis pigmentosa and ptosis [NARP], myoneurogenic
gastrointestinal encephalopathy [MNGIE], myocolonic epilepsy with ragged red fibers
[MERFF] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and
stroke-like syndrome [MELAS])
4. Alanine aminotransferase (ALT)>5x Upper Limit of Normal (ULN) OR aspartate
aminotransferase (AST) >5x ULN.
5. Body mass that exceeds the rating of the CT table.
6. Hypersensitivity to iodine.
7. Pregnant or breast-feeding.
8. Any condition that would put the patient at unreasonable risk in the opinion of the
Investigator.
We found this trial at
3
sites
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
University of Arizona The University of Arizona is a premier, public research university. Established in...
Click here to add this to my saved trials